These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18598191)

  • 1. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
    Assoumou L; Brun-Vézinet F; Cozzi-Lepri A; Kuritzkes D; Phillips A; Zolopa A; Degruttola V; Miller V; Costagliola D;
    J Infect Dis; 2008 Aug; 198(4):470-80. PubMed ID: 18598191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response.
    Cozzi-Lepri A;
    HIV Med; 2008 Jan; 9(1):27-40. PubMed ID: 18199170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.
    Treichel S; Hartmann M; Rump A; Brust J; Schuster D; Mosthaf F; Procaccianti M; Klinker H; Petzoldt D
    Eur J Med Res; 2003 Sep; 8(9):405-13. PubMed ID: 14555296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant genotype interpretation of resistance to didanosine.
    Marcelin AG; Flandre P; Pavie J; Schmidely N; Wirden M; Lada O; Chiche D; Molina JM; Calvez V;
    Antimicrob Agents Chemother; 2005 May; 49(5):1739-44. PubMed ID: 15855490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.
    Capdepont S; Aurillac-Lavignolle V; Faure M; Dupon M; Morlat P; Ragnaud JM; Chêne G; Fleury H; Masquelier B;
    J Clin Virol; 2006 May; 36(1):36-42. PubMed ID: 16513416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.
    Flandre P; Marcelin AG; Pavie J; Shmidely N; Wirden M; Lada O; Bernard MC; Molina JM; Calvez V
    Antivir Ther; 2005; 10(4):479-87. PubMed ID: 16038473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
    Assoumou L; Cozzi-Lepri A; Brun-Vézinet F; Degruttola V; Kuritzkes DR; Phillips A; Zolopa A; Miller V; Flandre P; Costagliola D;
    AIDS; 2010 Jan; 24(3):365-71. PubMed ID: 19864933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
    Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
    AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
    Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
    Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.
    Helm M; Walter H; Ehret R; Schmit JC; Kurowski M; Knechten H; Korn K; Braun P; Schmidt B
    Eur J Med Res; 2007 Jun; 12(6):231-42. PubMed ID: 17666312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.
    De Luca A; Giambenedetto SD; Trotta MP; Colafigli M; Prosperi M; Ruiz L; Baxter J; Clevenbergh P; Cauda R; Perno CF; Antinori A
    J Infect Dis; 2007 Dec; 196(11):1645-53. PubMed ID: 18008248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients.
    Flandre P; Costagliola D
    AIDS; 2006 Oct; 20(16):2118-20. PubMed ID: 17053360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
    Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A;
    J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of nine resistance interpretation systems for HIV-1 genotyping.
    Stürmer M; Doerr HW; Staszewski S; Preiser W
    Antivir Ther; 2003 Jun; 8(3):239-44. PubMed ID: 12924541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of artificial neural networks to predict virological response to combination HIV therapy.
    Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C
    Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.
    Svedhem V; Bergroth T; Lidman K; Sönnerborg A
    HIV Med; 2007 Nov; 8(8):504-10. PubMed ID: 17944683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.